i often get a stony silence from bio tech and pharma company ceos when i say that, because i think they take a somewhat more cautious perspective of this, and we could talk about why. but from my perspective this is great opportunity to enhance the decision making that professionals make in terms of how to use marketed drugs but also to make the whole enterprise of developing drugs better and more innovative and more efficient. now, why is that? the reason i say that is very simply the whole purpose of the capital markets, the investment markets is to direct investment capital to the most promising opportunities. and we all know, we've all seen the statistics about the hundreds of millions and dollars it cost to develop the drug and the very high failure rates that we have in the sector. every time that huge dollars are invested in a drug that does not ultimately succeed and get to patients, those are dollars that cannot be invested somewhere else. those were dollars that were in effect wasted. now, you're always going to have that happen because -- >> you can't be right all the time. >

purdue pharma declined our request for an on-camera interview, but said they're deeply troubled by the opioid crisis and are committed to working collaboratively to help solve it. jeff. >> to juliana and laura, thank you both for that reporting tonight. >>> now to some other stories we're following in the evening news feed. teeth and partial jaw bone found in a cave in israel may force scientists to reexamine the history of human migration. researchers today said the 2002 discovery may be 194,000 years old. that suggests humans could have left africa 100,000 years earlier than previously thought. >>> the coast guard is setting records for drug seizures. in san diego today, the coast guard showed off the cocaine seized in the pacific. since november, 47,000 pounds worth more than $721 million. >>> the engineer on that amtrak wreck in washington state last month has told investigators how it happened. he said he knew about a curve in the tracks, but missed warning signs that it was coming up until it was too late. the train, traveling 50 miles an hour above the speed limit, derailed, kil

again, it is a clear demonstration of the fact we're prioritizing pharma and r&d, because this is, you the point of our industry and gsk is to discover, develop, and distribute medicines that make meaningful differences at scale. we already lead in global respiratory, leading portfolio in hiv and are innovating well there, but the decisionswe hav to make are going to be about where we might want to play in terms of new specialty areas, whether that be oncology or immu kn -- immunization he's going to be looking in detail at that pipeline. and as i said previously, you know, we'll see what the data says, but also should we supplement it with some potentially external assets. you'll hear much more on that in the months and years to come >> stay tuned. thank you so much for being with us >> fantastic to be here, thank you. >> a lot more coming up, including on "halftime report" report, the ceo of celgene back to you. >> thank you very much for that. our meg terrell at jpmorgan's health care conference >>> let's send it back to a news update with sue herera sue? >> thank you so much here's

president trump: they're getting away with murder, pharma, pharma has a lot of lobbyists and a lot of power. liz: remember that? well, it turns out drug companies aren't the only ones still getting away with what the president called murder. they're starting the new year by using pricing as a weapon, amgen hiking its rheumatoid arthritis drug enbrel by 9.7% we have biogen tacking on another 8 % on to its multiple sclerosis drug and among them the popular avanex, and the most stunning cycle next source adding 1400% on to the price of its 40 year old life extending cancer drug. many accusing the company of price gouging cancer patients but this is just business and while president trump has said somethings got to be done and patients are furious, shareholders no doubt are thrilled by the idea that higher drug prices might mean bigger profits and stronger stock shares. which side wins out here? chip davis represents generic drug makers and is a consumer advocate. chip? listen to biogens of the world and the amgens and next sources nobody is stopping them the president has given pretty st

pharma and big money, what are the possible road blocks that you mentioned there?> they can certainly grow as independent companies and they can commercialize themselves and with the availability of capital, it works two ways, gentlemen, sanofi has the capital, and yes, big pharma, but also as edwin pointed out, he has raised money on nasdaq. and it is possible to build companies themselves and become potentially the next amgen of europe >> thank you very much >>> now, brexit talks come back into focus later today a meeting of the eu general affairs council. this in turn will provide the commission with a formal mandate to initiate talks with the uk on a transition period after brexit but brexit sector davis has played down in the uk, on terms of that, speaking in middlebrook, mr. davis said he's confident they can reach an agreement at the march european council, let's take a listen >> immediate goal, we will reach an agreement on the implementation period. and because it's largely the same, i'm confident political agreement can be reached at the march european co

this is no privacy this is this is profit over people's lives people's eyes people's health and big pharma owns our government they've captured the regulators the media the politicians and maybe just maybe this is one of the reasons american kids we just found out are seventy percent more likely to die before adulthood than kids in other rich countries maybe they're dying because they're all jumping off a bridge when they realize donald trump is president and the o.b. one could no be your only hope candidate is oprah winfrey. the no other feel your. t.v. star. talks. which we've pretty soon the head of the food and drug administration will be charlie sheen. and the surgeon general will be yakking from animaniacs. point even a toddler probably thinks. the cold dark abyss of nonexistence sounds better than this. speaking of the cold dark abyss during the bombsite clone kids in baltimore schools were sitting in forty degree classrooms because the city wouldn't pay for heating repairs but it's not just baltimore the american society of civil engineers.

philadelphia leaders believe this nightmare has been forced on them by big pharma the companies who make opioids and falsely marketed them as pain relief without at diction. >> the city currently in the grips of what can be termed as a public health nightmare. >> reporter: nightmare that's cost millions for police, first responders and treatment of the addicted. so the city has turn to the courts to get its money back. filing wednesday a 160 page lawsuit to match the size of the problem. >> today we're asking the companies that sell these drugs to stop pushing these drugs in philadelphia. and to start helping us clean up the problems they have caused. >> reporter: named are ten big drug makers like johnson & johnson, perdue pharma and endo health solutions and janson pharmaceuticals. they're accused of deceptive marketing and sale of prescription opioids. the city has linked with private law firms to do the heavy legal lifting in return for one third of any payout. >> i sell syringes to support my habit. this way i don't have to rob and steel or anything like that. >> reporter: back in f

meg terrell on the new innovations being made by pharma and biotech companies. but first, bertha coombs. >> reporter: i'm bertha coombs. 2018 will be another year of change and uncertainty in health care. here's what to watch. one, m&a, as in mergers and antitrust scrutiny, will be front and center. regulators flocked to the big insurance mergers saying they would hurt consumers. will they block cvs's deal to buy aetna? nonprofit hospita are gearing up for big deals too. they've approved more mega mergers as other play defense. two, amazon will impact the health care supply chain, whether or n the online giant gets into the pharmacy business. the scrutiny over price willing keep pressure on pharmacy benefit firms to hold down costs and prove their value. three, obamacare won't go away. doug jones' win in alabama makes the math even tougher for republicans to get enough votes in the senate for full repeal. but the trump administration can still make big changes at the edges, especially through state waivers on plan benefits. the lead-up to 2019 change in enrollme

there is no privacy this is this is profit over people's lives people's eyes people's health and big pharma owns our government they've captured the regulators the media the politicians and maybe just maybe this is one of the reasons american kids we just found out are seventy percent more likely to die before adulthood than kids in other.

this is a travesty this is this is profit over people's lives people's eyes people's health and big pharma odes our government they've captured the regulators the media the politicians and maybe just maybe this is one of the reasons american kids we just found out are seventy percent more likely to die before adulthood than kids in other rich countries maybe they're dying because they're all jumping off a bridge when they realize donald trump is president and the o.b. one could no be your only hope candidate is oprah winfrey. on the other field. yes. he'd start. hawkster. which we've pretty soon the head of the food and drug administration will be charlie sheen. and the surgeon general will be yakking from animaniacs. point even a toddler probably thinks. the cold dark abyss of nonexistence sounds better than this. speaking of the cold dark abyss during the bombsite clone kids in baltimore schools were sitting in forty degree classrooms because the city wouldn't pay for heating repairs but it's not just baltimore the american society of civil engineers found that more than half of the nati

purdue pharma declined our request for an on-camera interview, but said they're deeply troubled by the opioid crise and are committed to working collaboratively to help solve it. jeff. >> glor: to juliana and laura, thank you both for that reporting tonight. now to some other stories we're following in the evening newsfeed. teeth and partial jaw bone found in a cave in israel may force scientists to reexamine the history of human migration. researchers today said the 2002 discovery may be 194,000 years old. that suggests humans could have left africa 100,000 years earlier than previously thought. the coast guard is setting records for drug seizures. in san diego today, the coast guard showed off the cocaine seized in the pacific. since november, 47,000 pounds worth more than $721 million. the engineer on that amtrak wreck in washington state last month has told investigators how it happened. he said he knew about a curve in the tracks but missed warning signs that it was coming up until it was too late. the train, traveling 50 miles an hour above the speed limit, derailed, killing thre

boyd, to you first, pharma, not too happy with the president and nobody else might be. >> pharma willmore of its fair share of problems, which is a good thing because they've been employing an army of lobbyists which is collusion of the swamp which they're going to take a swing at. you saw in the press conference something important, liz, that not only was this about big companies doing well but getting it down to the little guy which is the messaging, getting it down to the small businesses, not just the big companies doing well and getting big bonuses to the family-owned business. this was a message that met the policy which is pretty rare for the administration thus far. liz: robin, it's a right of american passage that the opposing party from the president does not smile, stand, clap that much. i get that. because the republicans did it to president obama, but when you hear what we just heard from the oval office, and talking about anfinson, farm in iowa. the farm store. he had seven employees and was excited as a kid in a candy store. you've got to give props to what we see is th

pharma outfits almost never pull extra dollar per share a lot of it comes from the fact that business is very strong cfo bill chase explained on the conference call, rummira is growing. -- that is up 28% from just last year and abbvie sees hepatitis c business doubling. and mega ret is there new hep c cure abbvie is the kind of drug stock that is worth buying as it goes lower. it is an opportunity even if the new initiative from jeff bassos seems to be a serious threat companies like abbvie should be fine stocks being pulled down because of etfs. etfs created to mimic all of the drug stocks and get away with single stock risk. biotech focuses on neurological conditions autoimmune diseases the guidance was so good it sent the stock surging. biogen rallied. you are almost getting the latest numbers for free. biogen's headlines results were much on to write home about. still posted a 19 cent earnings miss management guidance was excellent. in these context of these quarter quarterly reports. bio gen indicated it would earn $24. so what is drooifing this credible strength? it is multiple

a lot of these pharmas reporting dollars. what can we expect in these factors?irst. roche closed the year with an m&a deal. we saw a few, not as many as thected, but roche ending last trading day of the year, announcing the acquisition of the u.s. biotech. nothing of russian size, but it got people excited again and we have the big health care conference that jpmorgan holds next week and everyone is deals, etc. you will continue to see cherub pharma among large small biotech's, but in terms of wholesale m&a, that will still end up being dependent on assets and specific needs of the pharma companies. science coming more in focus. sam: entirely. volatility is so much that two weeks later, what i write is irrelevant. whattrength of the euro is we need to keep an eye on. 1.22 ther is back at euro and it is one we need to think about when it comes to the euro reporting companies. it is important for the u.s. as they suffered from the strength of the dollar, now it has weakened and helped them. we saw that in q3 and i expected in q4 too. guy: we will look forward to t

day supply our drugs but don't make them here they're getting away with murder pharma, pharma has a lotf lobbies. a lot of lobbyists a lot of power and there's very little bidding on drugs we're the largest buyer of drugs in the world, and yet we don't bid properly we're going to start bidding and we're going to save billions of dollars over a period of time. >> so those comments were made on the wednesday of that conference, 9,000 health care investors all together watching televisions driving the ibb down 3% intraday on those comments. >> yeah, i'll openton to the floor, i mean, weiss, you, i'm sure, have many opinions on these stocks. >> i do. it's always interesting conference i've been there. i think what's most interesting, though, you'll see the biggest moves, are when they talk about their pipelines and they'll reveal some data that they have. i think that, you know, it's -- jimmy and i disagree on his, but pricing is an issue, and the drug companies still haven't reined it in so potentially could see another trump announcement, he's so geared into the market so maybe pharma wil

. >> i would love for purdue pharma and other drug companies to follow me around, just one day, give'll show you what you have done to the people in the state of ohio. >> reporter: purdue recently tried to persuade dewine to drop ohio's lawsuit and negotiate instead, writing, litigation takes years and the costs for both sides are significant. >> there's a lot at stake for them. and so they've been very aggressive. they've lawyered up. they have hired lobbyists. >> reporter: they've opened their war chests. donations from drug companies to political associations for state a gs have risen in the past three years totalling almost $700,000 to democrats and over $1.7 million to republicans. professor paul nuett studies state government. >> you have some of the very companies that have manufactured opioids either under active investigation or potentially under investigation, donating tens of thousands, hundreds of thousands of dollars, to these ag organizations. >> reporter: the republican ag association told us they have an obligation to the people to hear from all sides. their democrati

, pharma and so forth. and each was assigned to these seven domains. we actually get further into what we call subdomains, but i've left that out of this talk. and then we look at the percentage of crls that had a matching press release. question one was what's in the crl because nobody really knew. and the second part was given that we at the fda could see the crl, what was it that the public could see? what could they see in a press release? what percentage of the statements appear in the press release? or do they release a press release and if so, how much information was actually disclosed? and we actually look at the fcc filings to see if there was any supplementary information over there. again, the first question was why does the fda turn down a drug? and that a fundamental question to when there was no public answer. and in the absence of information there were at least some people who believed the drugs were sometimes not approved for lack of a crossed "t" or lack of a dotted "i." and our experienc

mark: let's stick with pharma. 2017 another active year in the industry group. joins us now.f oncology -- remind what it is. it is the new mode of trying to get your own immune system to attack the cancer that you have. that is the holy grail. we've been starting to see some development already. there are drugs on the market doing really well from hastol-myers, astra seneca some indications and pfizer has some indications. that's what this technology is trying to do. onslaught inave an lung cancer reporting from three companies -- merck, bristol meyer and rush. they are in a potentially better place -- it's currently viewed as being a distant third in this particular space. we see it in a better place to report data engage some lead back in lung cancer. mark: there was a divergence of performance in that share price. sam: right. mark: why was that? sam: the one that sticks out particularly is merck. it highlights the issue they have in 2018. they are so dependent for their ofwth through a period difficulty with patent expires -- even the mention of a delay in the reporting of

outlier orterally an would you make the same accusation of all big pharma? of big pharma would have to look in the mirror and justify their price increases and really struggle to do it in terms of improving value. erik: that is tim wentworth. of expresseo scripts. we are live from the jpmorgan health care conference in san francisco. many more interviews coming your way. schatzkeranks to erik in san francisco. i want to mention that at 2:30 eastern eric is going to be back. he will be speaking with the ceo of medicare and medicaid provider 17. aesident trump is hosting bipartisan meeting on immigration at the white house. headlines have been crossing and president saying that representative bob goodlatte from virginia will be submitted immigration bill in the next few days. he also talked about the need -- wall for aaw fairly good portion. new york times is reporting that president donald trump will attend the world economic forum. this is particularly interesting as the president would have run as the anti-davos man. this is bloomberg. ♪ vonnie: president t

disruption of medical companies, big-cap pharma this is a big -- it's going to -- >>> for more on theade let's bring in our pot master, tim seemo? seymour hey, tim >> system my new moniker >> you're in ethereum and pot stocks, but fresh money white now, what is a better bet? >> i think value way iist i thi they see are valuations. i'm not going to tell you, if you look at canopy or aurora or gw pharma, they're not cheap, but in some case they haven't even begun to price in efficacy on a lot of the pain relief. whether it's epps lensy or industries that are starting to find application for this, that's the story here. it's not to me all that recreational in i think the legalization has been a catalyst, but the medical side has been a about ig de. the top four names make up 30, 40 percent, those names, you know, they are four, five, 6 billion companies, right now that's one way to get good exposure. >> when you're looking at the individual stocks, tim, is it important that these stocks are based or much of their business is in canada versus the united stat states. >>> my view is if you

as you mentioned pharma continued to perform well and by the way products within pharma continued to grow. new products are being filed for approval and we expect two new approvals next year. that led to the pharma growth we are already experiencing. --a: can you give us a sense you said you're going to see a benefit from the tax overhaul. you didn't give a sense of what you are going to use the extra money for. jpmorgan is using it to increase salaries for employees. what about you? we expect to increase our investment in innovation. world's largest and most diversified health-care company the best that we can do with the money that comes to us from the very favorable treatment for overseas earnings and lower tax rate is two invents more in innovation -- to invest more in innovation. we're going to invest more incrementally in innovation than we ever have before. lisa: does that mean that you are going to be making more acquisitions after the deal or that you are going to be hiring more people opening more plants? what does that mean and how much money are you talking about? >> we t

is more pharma made to come?n a reboot as the largest wealth manager promises a $2.1 billion stock buyback. the markets remain unimpressed. welcome to "bloomberg markets: open."opean i'm matt miller. stockeally individual names we are talking about. ooil and gas, well bid. we;ll talk about that with david sneddon. the market has a lot of shorts on in the retail space. a, we have got a interesting news flow and b, it's a sector. trading lower. thanks also down. take a look at the ubs chart. market is not impresses morning. we're working our way through towards the close of the session. let's get the bloomberg first word news update. reporter: u.s. lawmakers have failed to negotiate the end to the government shutdown, despite the bipartisan efforts to broker a deal. federal agencies begin closing at the start of the normal work week. ofs reflects frantic efforts the publicans and democrats to blame one another. buyback as soon as $1.2 billion of stocks over the next three years. the by that program will begin .n ma

. >> reporter: named are ten drug makers like johnson & johnson, perdue pharma and endo health solutions deceptive marketing and sale of prescription opioids. the city has partnered with private law firms which will get a third of any money won in what's likely to be a long battle. >> sell syringes to support my habit. this way i don't have to rob and steal or anything like that. >> reporter: back in kensington, jack shouts works to users looking for clean syring syringes. he's got plenty of takers. >> it's bad. >> reporter: gotten better at all. >> it's bad. no, not at all. it's bad. >> reporter: losing friends. >> oh, yeah. i lost lot of people in the last year. >> reporter: fox 29 contacted the companies named in the suit perdue pharma says it vigorously denies the allegations and looks forward to presenting its defense. alert again says it supports the safe responsible use of prescription medications. janssen says the allegations in the lawsuit are both legally and factually unfounded. >>> i'm jeff cole fox 29 news. >>> a major drug trafficking operation busted the montgomery county

interest coming in to sell marijuana, have you jersey folkn commercial real estate that are seeing as a pharma economy, we learned from other states we're not going to be we're headed to this we will legalize. >> it >> i don't see it. >> it is going to happen. >> he congress to look at this. hislawmakers in democratic not a done deal. bill: so, fresh, cran ber cannabis? >> nothing that can replace tom. bill: fair enough. >> all right, thank you, scott, appreciate it. luck, you got a t ahead. >> got it. bill: not too much don't agree, but. >> let's check out headlines we're chasing tonight. >> new york city looking to open up safi jec -- safe-inject sites. philadelphia is already seeking out said operators establish safe sites, oprah winfrey speect of buzz about her potential for. in style magazine said that oprah has no plans to run, say it is not something that interests me, i don't have the dna for it. >> can you make a horse return home, a deputy videotaped animal running down the road, he pleads for the animal to stop. >> stop, fleece. please. >> the horse was returned to its owner. >> and

among the companies being sued are purdue pharma, which is the maker of oxycontin, and johnson & johnson. the opioid crisis killed 64,000 americans in 2016. meanwhile, photographer nan goldin, who is a recovered opioid addict, and a group of her fellow artists and activists has launched a campaign shaming the secretive sackler family -- which owns purdue pharma -- over their profiting off the opioid crisis. "i don't know how they liveve wh themselves congo she said. in libya, a double car bombing in the city of benghazi has killed at least 33 people. the first explosion hit a mosque asas worshipers were leaeaving evening prayers. the second bomb exploded only minutes later as health and security officials were arriving at the site of the first blast. in news on syria, the u.s.-led coalition fighting isis claims it killed more than 150 isis fighters in airstrikes on saturday in syria's south-eastern province of deir deir al-zour. meanwhile, in the northernrn syrian c city a afrin, turkrkes continuing its bombing and ground offensive against the u.s.-backed kurdish forces who control the r

after resigning from the council, prompting president trump to tweet now that ken frazier of merck pharma has resigned from president's manufacturing council, he will have more time to lower ripoff drug prices. here's what he said. >> we continue to work with congress and the administration on working for patients. we continue to work effectively with the administration as well as with congress on those issues >> were you surprised or insulted when the president got personal >> no, i can't say i was surprised. you know, i made my statement and the president made his statement in response. >> checking on merck stock, it's down more than 6% since president trump was elected. it's currently flat. back over to you >> thank you very much for that. >>> on march 28th, cnbc will host our first ever healthcare conference, it's called healthy returns, investing in healthcare innovation it will feature top government officials, ceo and investors in the short-term, today, the jpmorgan healthcare conference continues. and cnbc's coverage will continue. >>> we're just getting started on "worldwide exch

david: we did a big strategic review of the pharma portfolios.one or two areas that we have decided to do prioritize -- to deprioritize. we have really been the leader. that will not be an outright investment that we think there probably is a different sort of partner that really focuses and prioritizes in that area. more of a partnership arrangement. prioritized. that's true. eric: you mentioned am a, your new -- emma, your new ceo. what has changed out of your leadership? david: some things have not changed. she is very much supportive of three businesses. spends a lot of time having a detailed look at gs k, really reinforced our values that are important to the vast majority across the world. on is extremely focused performance, and she has tightened up how we operate the matrices, accountability, decision-making rights and brought a lot of some of the consumer health care's discipline on the supply chain. the way we manage inventory. above all, she has put pharma r&d as her number one priority to really get that moving and develop great new m

the price starts at ormat is 10% upside >> all right, valeant is up 60% so what is next for the pharmampany in wll te'alk to the ceo, joe papa, straight ahead on "power lunch." room. your privacy makes you my number 1 place to go number 2. i love you, but sometimes you stink. febreze air effects doesn't just mask, it cleans away odors. because the things you love the most can stink. and try febreze small spaces to clean away odors for up to 30 days. breathe happy with febreze. >>> hello everyone, i am sue herrera. here is your cnbc news update. christopher ray addressing the cyber security conference in new york saying it is imperative law enforcement agencies and tech companies work together to strike a balance for privacy and security >> let me be clear that the fbi supports information security, we support strong encryption information security programs need to be thoughtfully designed so they don't under mind the lawful tool that is we need to keep this country safe >> 85-year-old joe arpaio, arizona sheriff received a pardon from president trump says he's running for the senate. h

multiple subsectors from insurers to drugstore chains to big pharma painting the broader markets a deep shade of blood red. president loves to watch the stock market, not sure he's loving this first major sell-off of 2018 coming just as he gears up to deliver very first state of the union address to the american people, scheduled for six hours from now. we know that he is rehearsing for the big speech as we speak. no doubt ready to take a big victory lap as the job market, the stock market and tax reform have done great things so far for the country, but could today's sell-off inspire him or force him to make any last minute edits? >>> plus can he deliver a plea to both sides of the aisle in order to kick his 2018 economic agenda into full gear? fair and balanced. we'll hear from two congress members in leadership positions who will be front and center at the state of the union address tonight. >>> plus apple rocked to the core and charlie is about to break big news from washington, d.c. less than an hour to the closing bell. let's start the "countdown." . >>> we are just getting this b

and that's exec we were farm i -- that is exactly what big pharma did with $150 million in ad buys. they supported the passage of obamacare because they knew it would not touch them. this is at a time when prescription drug prices in this country are at an all-time high, in fact, they are one of the major drivers of health care costs in america. so even if you take a moment like that, where you have the african-american president first elected, democrats are running the house, democrats are running the senate, they have this big dream of getting health care done, something that harry truman talked about and couldn't make happen, bill clinton and hillary clinton talked about and make happen, finally bakr obama -- barack obama tries to do it and the first thing they do is exempt one big industry because they cannot tackle both at the same time. one would argue that they did not really tackle the insurance industry either because insurance company stocks have nearly doubled since obamacare became law. when you talk about the environment. you know bill mckibben, the guy , who started 35

take a look at pharma. interesting m & a activity in european pharma.ofi agreeing to acquire ablynx the global bond selloff also continues. take a look at the german five year yield touching positive territory for the first time since late 2015 on this expectation that central banks will begin unwinding stimulus. and this expectation of this unwinding that has resulted in the euro gaining momentum against the u.s. dollar. yes, slightly lower today. but still up 3% for the year take a look at the uk pound. higher by 4% in 2018 though some analysts saying the trajectory could being complicated by uncertainty around uk politics 140 for the pound. back to you. >> thank you >>> and some controversy meanwhile over fitness trackers making news this morning are the devices and apps revealing sensitive military information nbc's ha ns nichols has the latest. >> there is a global heat map that is pout out where you can compare and compete with fellow runners or bikers. the issue is that a lot of u.s. military personnel use it. they've been using it and not turnin

. >> reporter: named are ten drug makers like johnson & johnson, purdue pharma and endo health solutions. they're accused of deceptive marking and sale of prescription opioids. the city has partnered with private law firms which will get a third of any money won in what's likely to be a long battle. >> i saw syringes to support my habit. this way i don't have to rob and steel or anything like that. >> reporter: back in kensington jack shouts works to users looking for clean syringes. he's got plenty of takers. >> it's bad. rot. >> reporter: got tepp better at you. >> no, not at all. it's bad. >> reporter: losing friends? >> oh yeah. lost a lot of people in the last year. >> reporter: fox 29 has contacted the companies name in the suit purdue pharma vigorously denies the allegation and looks forward to presenting its defense. allergan says it sports the safe responsible use of prescription medications. janson says the allegations in the lawsuit are goal legally and factually unfounded. we'll have more at 6:00. i'm jeff cole fox 29 news. lucy. >> okay. talk then, jeff. >>> violence in west

french pharma ferm sanofi buying a biotech company for $11.6 billion.e have seen $170 billion of across border deals between the united states and european companies in 2017. guys, back to you. >> thank you very much when we come back, about 30 minutes to go until that senate vote that could end the shutdown stanford university director of domestic policy lanhee chen joins us to weigh n and the s&p 500 on the track for the best january since 1997 the dow is just about flat a this point "squawk alley" back right after this >>> hello, everyone. here's your cnbc news update at this hour. japan has spotted a north korean ship obtaining oil in defiance of united nation's sanctions a patrol plane spotted the tanker on saturday saddled up to another tanker with a registry in the dominican republic. tokyo officials conducting a missile attack drill to prepare that city for the possibility of a north korean strike. 350 people participated. and when the alarm sounded, they took cover in underground locationors buildings. it is the first such drill to take place i

barry was a pioneering drug tycoon eager to take on big pharma and his wife a patron to many charitiesway millions to causes. all that more horrific that they died in such a way. the children have launched an independent investigation of their own. they said that their preliminary findings are consistent with the police. >> reporter: the shermans had relations with prime ministers both past and present and it has left many shake even wondering by whom and why. paula newton, cnn. >>> you are watching "cnn newsroom." found in light. it makes us feel alive. it illuminates our world and connects us to each other. with transitions® adaptive lenses® you'll live the good light. they block uv rays. plus they help protect from harmful blue light. both indoors... and out. enjoy life more comfortably. enjoy life more richly. live the good light. find an eyecare professional at transitions.com we use so why do we pay touters thave a phone connected. when we're already paying for internet? shouldn't it all just be one thing? that's why xfinity mobile comes with your internet. you can get 5 lines of

in pharma cultivates vegetables and herbs in computer controlled modules on location in supermarkets or restaurants the data collected on growth and consumption is aimed at obtaining a perfect match between cultivation and demand. but while in farms data volumes are growing only slowly online retailer outfitter a has collected enormous amounts. outfitter restyle lists put together wardrobes for half a million men from eight countries entirely according to their taste and needs. machine learning helps the stylists cater to a customer's taste more accurately with each order. the software gradually restricts the available selection based on the knowledge of goods previously ordered and returned. stephen lam is outfitter east chief data officer he says adopting intelligent software has improved sales though it still wouldn't be possible to replace the online retailers one hundred fifty stylists with computers. we want to create the perfect symbiosis between stylist and machine a stylist will always be able to do things better than any algorithm such as recognizing trends and the entire c

also fascinating the price tag the pharma industry generally puts on life saving medication for most patients especially in the developing world they're way out of reach no question about that the interesting part is how companies justify raking in all those juicy profits. for years this man suffered from hepatitis c. a viral disease that was destroying his liver. he was forced to spend most of his time in bed. he doesn't want to be identified by name. i get up with my wife at six am have a cup of coffee down again later i go out with the dog for a short walk and was so exhausted that i had to go back to bed. he doesn't know how he contract to this contagious disease. but his doctor provided him with a cure. in twenty fourteen a drug came onto the market which for the first time was able to eliminate hepatitis c. from the body. blocks the ability of the virus to reproduce and usually after a few weeks there is no trace of it in the patient's blood. dr stefan doctor says a two month course of treatment costs forty thousand euros a price tag he finds unconscionable production costs he

. >>> the health care company array bio pharma is promising results from its study that tested the effectiveness in treating colorectal cancer. is resulted in an unprecedented progression-free survival and response rate. shares took off at 18% to 1556. >>> french drugmaker sanafee is buying a company for more than $11 billion as it expands its portfolio. shares fell 3% to 4320. meanwhile, bioferativ was up to 103.79. and celgene has agreed to sell a company that gives them access to gene therapy cancer treatments. shares were up a fraction to 102.21. >>> towns and cities across the country are getting hit and hard by the flu. but some big companies are doing what they can to fight back. here's the big business behind the big illness. >> reporter: flu is widespread. while flu brings misery to those suffering for it, for some segments, flu season brings healthy returns. hospitals and urgent care clinics see an uptick. lab testing firms and makers of diagnostic tests get a boost. the same goes for pharmacies and customers visit for medications, flu shots and supplies. and finally, makers of flu vac

health kit while amazon is quietly moving in for the moment and facebook is making it easier for pharmao advertise. healt executives themselves are thinking about disruption and innovation in terms of technology. biogen ceo says the biotech industry needs to take the lead in changes and be what he calls the tesla of the industry and set new models. >> we need to bring this industry closer to the consumer, closer to the patients. we are meant to provide support to the patient who is sick, not to take advathose. >> reporter: some analysts say the road ahead for tech and health care won't be without bumps as they learn to understand regulatory procedures and patient/clinician relationships. fo "nightly business r i'm deirdre boza, san francisco. >> still ahead, screen time. should apple curb growing smar >>> two prominent apple shareholders made an unusual request. they pressuring the company on a social responsibility issue not a corporate one. the focus is on children and whether the company should do more fight smartphone addiction in kids. josh lipton has the story. >> reporter: belie